An Inconvenient Truth About the LVEF and Cardiac Monitoring in Oncology: Please Don't Shoot the Messenger!
- PMID: 36752437
- DOI: 10.1016/j.jcmg.2022.11.017
An Inconvenient Truth About the LVEF and Cardiac Monitoring in Oncology: Please Don't Shoot the Messenger!
Keywords: GLS; LVEF; cancer; cancer treatment-related cardiac dysfunction (CTRCD); heart failure.
Conflict of interest statement
Funding Support and Author Disclosures Dr López-Fernández has received speaker fees from Philips, Janssen, and Incyte not related to the current work. Dr Barac has reported that she has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial.JACC Cardiovasc Imaging. 2023 Mar;16(3):269-278. doi: 10.1016/j.jcmg.2022.10.010. Epub 2022 Nov 16. JACC Cardiovasc Imaging. 2023. PMID: 36435732 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous